We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+3.75%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$218B
AUM Growth
+$17B
Cap. Flow
+$6.68B
Cap. Flow %
3.06%
Top 10 Hldgs %
22.81%
Holding
10,425
New
1,217
Increased
3,775
Reduced
3,854
Closed
1,335

Top Buys

Rank Stock Value
1
NFLX icon
Netflix
NFLX
+$400M
2
C icon
Citigroup
C
+$395M
3
CELG
Celgene Corp
CELG
+$360M
4
AMZN icon
Amazon
AMZN
+$347M
5
RTX icon
RTX Corp
RTX
+$344M

Sector Composition

Rank Sector Weight
1 Technology 5.61%
2 Financials 4.93%
3 Healthcare 4%
4 Consumer Discretionary 3.82%
5 Industrials 3.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HZN
8451
DELISTED
Horizon Global Corporation
HZN
$69K ﹤0.01%
19,258
-37,961
-66% -$124K
RUHN
8452
DELISTED
Ruhnn Holding Limited American Depositary Shares
RUHN
$69K ﹤0.01%
+20,042
New +$103K
MOBL
8453
PUT
DELISTED
MobileIron, Inc.
MOBL
$69K ﹤0.01%
+11,100
New +$62.8K
ALDX icon
8454
Aldeyra Therapeutics
ALDX
$94.1M
$68K ﹤0.01%
11,405
-21,503
-65% -$162K
LUMO
8455
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$68K ﹤0.01%
5,136
+1,810
+54% +$27.3K
GNCA
8456
DELISTED
Genocea Biosciences, Inc.
GNCA
$68K ﹤0.01%
+17,290
New +$90.2K
LAC
8457
DELISTED
Lithium Americas Corp. Common Shares
LAC
$68K ﹤0.01%
16,735
+4,301
+35% +$17K
ABEV icon
8458
PUT
Ambev
ABEV
$43.2B
$67K ﹤0.01%
+14,300
New +$64.1K
QUIK icon
8459
QuickLogic
QUIK
$234M
$67K ﹤0.01%
8,310
-1,418
-15% -$14.3K
TTNP
8460
CALL
DELISTED
Titan Pharmaceuticals
TTNP
$67K ﹤0.01%
87
+11
+14% +$10.1K
ACER
8461
DELISTED
Acer Therapeutics Inc
ACER
$67K ﹤0.01%
+17,078
New +$325K
NBRV
8462
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$67K ﹤0.01%
+110
New +$67.5K
AGEN
8463
PUT
Agenus
AGEN
$329M
$66K ﹤0.01%
1,116
-1,212
-52% -$66.2K
BCLI
8464
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$66K ﹤0.01%
1,121
+194
+21% +$11.3K
ADMS
8465
PUT
DELISTED
Adamas Pharmaceuticals
ADMS
$66K ﹤0.01%
10,600
-400
-4% -$2.3K
IGC icon
8466
IGC Pharma
IGC
$31.1M
$65K ﹤0.01%
+39,579
New +$55.9K
SJT
8467
PUT
San Juan Basin Royalty Trust
SJT
$131M
$65K ﹤0.01%
16,900
-20,200
-54% -$89.4K
SLDB icon
8468
PUT
Solid Biosciences
SLDB
$986M
$64K ﹤0.01%
747
-220
-23% -$24K
AUC
8469
ATIF Holdings
AUC
$72M
$64K ﹤0.01%
+213
New +$74.8K
HTGM
8470
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$64K ﹤0.01%
214
+130
+155% +$54.2K
MR
8471
CALL
DELISTED
Montage Resources Corporation Common Stock
MR
$63K ﹤0.01%
10,300
-20,400
-66% -$203K
AVDL
8472
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
$62K ﹤0.01%
+21,600
New +$37.1K
ITI
8473
DELISTED
Iteris, Inc.
ITI
$62K ﹤0.01%
+11,864
New +$56.9K
TTOO
8474
DELISTED
T2 Biosystems, Inc
TTOO
$62K ﹤0.01%
+7
New +$82K
ENT
8475
DELISTED
Global Eagle Entertainment Inc.
ENT
$61K ﹤0.01%
3,748
-566
-13% -$10.2K

Similar funds

Ken Griffin's Q2 2019 Portfolio in Review

As of Q2 2019, Ken Griffin held 10,425 positions worth $218B, up 8.5% from $201B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Ken Griffin deployed $6.68B of net new capital in Q2 2019, opening 1,217 new positions and adding to 3,775 existing holdings. Its largest new stake was Uber: 7,077,910 shares worth $328M.

By sector, the portfolio is most concentrated in Technology at 5.6% of assets, down from 6% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Eli Lilly, an estimated $397M trimmed.

  • Ken Griffin's largest Q2 2019 buy was Uber: 7,077,910 shares worth $328M.
  • Ken Griffin added most to Netflix in Q2 2019, an estimated $400M increase.
  • Ken Griffin's biggest Q2 2019 reduction was Eli Lilly, cutting an estimated $397M.
  • Ken Griffin fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $349M.
  • Ken Griffin's ten largest holdings make up 23% of its $218B portfolio in Q2 2019.
  • Ken Griffin opened 1,217 new positions and closed 1,335 in Q2 2019.
  • Ken Griffin's portfolio value rose 8.5% quarter-over-quarter to $218B.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.